FoldRx Technology Enables Discovery of Novel Therapeutic Approach for Treating Cystic Fibrosis

FoldRx Pharmaceuticals, Inc. (FoldRx) announced that it has discovered a series of novel drug prototypes that have shown potential in vitro to correct the protein-folding defect associated with cystic fibrosis (CF). The discovery, made through a research collaboration announced last year with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, may pave the way to novel drugs capable of repairing the protein misfolding associated with cystic fibrosis, thus helping treat the underlying cause of the disease. The discovery was made using FoldRx's proprietary yeast-based, high throughput screening platform.

"We are...

Want to see the full article?

• Purchase this article for only $3.00